NCT06461403Completed
Inhaler Trainer Efficacy Study
Inhaler Trainer Efficacy Study: Interactive Training Tool Providing Technique Feedback for COPD/Asthma Medication Delivery
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
This will be a randomized, controlled, clinical trial. The investigators aim to determine the feasibility of and efficacy of the Inhaler Trainer Device for ongoing inhaler skill training. The research team will enroll 140 patients from the inpatient or outpatient setting from the University of Chicago Medicine over the course of up to 12 months. Participants will complete assessments, a lung function test via spirometry, and inhaler education via either the Inhaler Trainer Device learning program or Brief Intervention. All participants will return at 6 weeks (window of +/- one week) post-initial inhaler education for an in-person evaluation of their inhaler skills, lung function, and acute care utilization. Finally, a post-study semi-structured interview will be conducted to gather feedback on the device after the 6-week visit has been completed.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 12 Apr 2024
- Start date
- 9 Oct 2025
- Primary completion date
- 28 Apr 2026
- Lead sponsor
- Koronis Biomedical Technologies
- NCT number
- NCT06461403
What you commit to
- Study type: Interventional
- Participants enrolled: 10
- From 9 Oct 2025 to the primary completion date, 28 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient unable to provide consent (e.g., history of cognitive impairment, unable to understand English) or declines to provide consent
Other
- Physician declines to provide assent
- Does not meet inclusion criteria
Who the study is looking for
- Age 18-85
- Physician diagnosis of COPD or asthma
- Has been prescribed or is being prescribed one of the inhalers listed below (DPI inhaler product, Active pharmaceutical ingredient):
- Serevent®Diskus®(GSK), Salmeterol
- Incruse Ellipta (GSK), Umeclidinium
- Spiriva Handihaler (BIP),Tiotropium
- Tudorza Pressair (AstraZeneca), Aclidinium
- Inexperienced with inhaler trainer device (defined by never having had inhaler training using an auxiliary tool besides an actual inhaler and spacer)
Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.